Potassium Carbonate → HCID 59333720, Verbindung

Reaktionsgleichung

[CH3:1][O:2][C:3]1[CH:4]=[C:5]([NH:15][C:16]([NH2:18])=[NH:17])[CH:6]=[CH:7][C:8]=1[N:9]1[CH:13]=[C:12]([CH3:14])[N:11]=[CH:10]1.C(=O)([O-])[O-].[K+].[K+].[CH3:25][C:26]1[CH:30]=[C:29]([CH3:31])[N:28]([CH:32]([CH3:49])[C:33]([CH:35]2[C:40](=O)[CH2:39][CH2:38][N:37]([C:42]([O:44][C:45]([CH3:48])([CH3:47])[CH3:46])=[O:43])[CH2:36]2)=O)[N:27]=1>CCO>[CH3:25][C:26]1[CH:30]=[C:29]([CH3:31])[N:28]([CH:32]([C:33]2[C:35]3[CH2:36][N:37]([C:42]([O:44][C:45]([CH3:46])([CH3:48])[CH3:47])=[O:43])[CH2:38][CH2:39][C:40]=3[N:17]=[C:16]([NH:15][C:5]3[CH:6]=[CH:7][C:8]([N:9]4[CH:13]=[C:12]([CH3:14])[N:11]=[CH:10]4)=[C:3]([O:2][CH3:1])[CH:4]=3)[N:18]=2)[CH3:49])[N:27]=1

Komponenten

Versuchsvorschrift

1-(3-Methoxy-4-(4-methyl-1H- imidazol-1-yl)phenyl)guanidine (175 mg, 0.57 mmol) and potassium carbonate (196 mg, 1.42 mmol) in EtOH (7 mL) were heated to 50° C. and tert-butyl 3-(2-(3,5-dimethyl-1H-pyrazol-1-yl)propanoyl)-4-oxopiperidine-1-carboxylate (248 mg, 0.71 mmol) added. The reaction mixture was stirred overnight. The solvent was evaporated and DCM added. The organic phase was washed with water and concentrated. The crude product was used as such in next step (450 mg, 113%).